Almirall and Forest report preliminary topline results from the ACCORD COPD II Phase III study of aclidinium bromide in Chronic Obstructive Pulmonary Disease (COPD) - Drugs.com MedNews
Links shared publicly online about this topic.
- 766total visits
Almirall and Forest report preliminary topline results from the ACCORD COPD II Phase III study of aclidinium bromide in Chronic Obstructive Pulmonary Disease (COPD) - Drugs.com MedNews
Barcelona and New York, October 29, 2010.- Almirall, S.A. (ALM.MC) and Forest Laboratories, Inc. (NYSE FRX) today announced top-line results from ACCORD COPD II
View full resource at drugs.com
Tags: COPD, Disease and Condition, Drug, Forest Laboratories, Pulmonology, disease
Most Recently Shared on October 29, 2010 at 2:15 pm By:
Almirall and Forest report preliminary topline results from the ACCORD COPD II Phase III study of aclidinium ... http://bit.ly/dvqUed #drug
Advertisement
